Email Alert RSS
Volume 11 Issue 6
Nov.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(6): 659-664
JIN Fan, XIE Jing, CHEN Rui, WANG Huan-ling. Progress of Remdesivir in the Treatment of Coronavirus Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 659-664. doi: 10.3969/j.issn.1674-9081.20200034
Citation: JIN Fan, XIE Jing, CHEN Rui, WANG Huan-ling. Progress of Remdesivir in the Treatment of Coronavirus Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(6): 659-664. doi: 10.3969/j.issn.1674-9081.20200034
shu

Progress of Remdesivir in the Treatment of Coronavirus Infection

doi: 10.3969/j.issn.1674-9081.20200034
  • 1.

    Department of Infection Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: WANG Huan-ling  Tel: 86-10-69158360, E-mail: wanghuanling@pumch.cn
  • Received Date: 2020-02-17
  • Accepted Date: 2020-02-23
    • Available Online: 2020-02-28
  • Publish Date: 2020-11-30
    Abstract
  • In December 2019, the outbreak of coronavirus disease 2019(COVID-19)occurred in Wuhan, China. It became the third outbreak of coronavirus infection after severe acute respiratory syndrome(SARS)and Middle East respiratory syndrome(MERS)in the past decade. COVID-19 is caused by 2019-novel coronavirus(2019-nCoV)infection that has spread rapidly and extensively.2019-nCoV is highly contagious, but there is no specific antiviral drug for coronavirus at present. Remdesivir, a nucleoside analogue, showed anti-SARS-CoV and anti-MERS-CoV activities in vitro and in animal models, and showed no obvious adverse reaction in the multicenter, randomized, controlled clinical trial of Ebola virus infection. Remdesivir is considered to be the great promising drug for treating 2019-nCoV infection. This article reviewed the research history and potential clinical applications of remdesivir in the treatment of coronavirus infection.
    • FullText(HTML)
  • loading
    • References(25)
  • [1] van Boheemen S, de Graaf M, Lauber C, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans[J]. mBio, 2012, 3:e00473-e00412.
    [2] Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle[J]. J Med Virol, 2020, 92:401-402.
    [3] Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States[J]. N Engl J Med, 2020, 382:929-936.
    [4] Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses[J]. Sci Transl Med, 2017, 9:eaal3653.
    [5] Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral remdesivir(GS-5734)Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease[J]. mBio, 2018, 9:e00221-e00218.
    [6] Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020, 11:222.
    [7] World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 [EB/OL]. http://www.who.int/csr/sars/country/table2004_04_21/en/.
    [8] World Health Organization. MERS situation update 2019[EB/OL]. http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.
    [9] Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak[J]. Emerg Microbes Infect, 2020, 9:313-319.
    [10] Woo PC, Lau SK, Huang Y, et al. Coronavirus diversity, phylogeny and interspecies jumping[J]. Exp Biol Med(Maywood), 2009, 234:1117-1127.
    [11] Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus[J]. Microbiol Mol Biol Rev, 2005, 69:635.
    [12] Bonavia A, Zelus BD, Wentworth DE, et al. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E[J]. J Virol, 2003, 77:2530-2538.
    [13] Zumla A, Chan JF, Azhar EI, et al. Coronaviruses-drug discovery and therapeutic options[J]. Nat Rev Drug Discov, 2016, 15:327-347.
    [14] Chu CK, Gadthula S, Chen X, et al. Antiviral activity of nucleoside analogues against SARS-coronavirus(SARS-coV)[J]. Antivir Chem Chemother, 2006, 17:285-289.
    [15] Cho A, Saunders OL, Butler T, et al. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7, 9-dideazaadenosine C-nucleosides[J]. Bioorg Med Chem Lett, 2012, 22, 2705-2707.
    [16] de Wilde AH, Snijder EJ, Kikkert M, et al. Host Factors in Coronavirus Replication[J]. Curr Top Microbiol Immunol, 2018, 419:1-42.
    [17] Sims AC, Baric RS, Yount B, et al. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia:role of ciliated cells in viral spread in the conducting airways of the lungs[J]. J Virol, 2005, 79:15511-15524.
    [18] Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J]. Cell Res, 2020, 130:269-271.
    [19] World Health Organization. Summaries of evidence from selected experimental therapeutics[EB/OL]. https://www.who.int/ebola/drc-2018/treatments-approved-for-compassi-onate-use-update/en/.
    [20] Mulangu S, Dodd LE, Davey RT, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics[J]. N Engl J Med, 2019, 381:2293-2303.
    [21] Chan JFW, Yuan SF, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission:a study of a family cluster[J]. Lancet, 2020, 395:514-523.
    [22] Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395:497-506.
    [23] Clinical Trials. Severe 2019-nCoV Remdesivir RCT[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04257656?term=remdesivir&draw=2&rank=1.
    [24] Clinical Trials. Mild/Moderate 2019-nCoV Remdesivir RCT[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04252664?term=remdesivir&draw=2&rank=2.
    [25] Clinical Trials. Adaptive COVID-19 Treatment Trial[EB/OL]. https://clinicaltrials.gov/ct2/show/NCT04280705?cond=Adaptive+COVID-19+Treatment+Trial&draw=2&rank=1.
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (283) PDF downloads(26) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return